• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MtClpC1N 端结构域与抗结核天然肽 Lassomycin 的复合物的晶体结构

Crystal structure of the N-terminal domain of MtClpC1 in complex with the anti-mycobacterial natural peptide Lassomycin.

机构信息

Division of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar 751023, Odisha, India; Post-Graduate Department of Biotechnology, Utkal University, Bhubaneswar 751004, Odisha, India.

Division of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar 751023, Odisha, India.

出版信息

Int J Biol Macromol. 2023 Dec 31;253(Pt 2):126771. doi: 10.1016/j.ijbiomac.2023.126771. Epub 2023 Sep 6.

DOI:10.1016/j.ijbiomac.2023.126771
PMID:37683752
Abstract

Antibiotics form our frontline therapy against disease-causing bacteria. Unfortunately, antibiotic resistance is becoming more common, threatening a future where these medications can no longer cure infections. Furthermore, the emergence of multidrug-resistant (MDR), totally drug-resistant (TDR), and extensively drug-resistant (XDR) tuberculosis has increased the urgency of discovering new therapeutic leads with unique modes of action. Some natural peptides derived from actinomycetes, such as Cyclomarin A, Lassomycin, Rufomycin I, and Ecumicin, have potent and specific bactericidal activity against Mycobacterium tuberculosis, with the specificity owing to the fact that these peptides target the ClpC1 ATPase, an essential enzyme in mycobacteria, and inhibit/activate the proteolytic activity of the ClpC1/P1/P2 complex that participates in protein homeostasis. Here, we report the high-resolution crystal structure of the N-terminal domain of ClpC1 (ClpC1 NTD) in complex with Lassomycin, showing the specific binding mode of Lassomycin. In addition, the work also compares the Lassomycin complex structure with the previously known structures of ClpC1 NTD in complex with other natural peptides such as Cyclomarin A, Rufomycin I, and Ecumicin.

摘要

抗生素是我们对抗致病细菌的一线治疗药物。不幸的是,抗生素耐药性变得越来越普遍,威胁着这些药物将不再能够治愈感染的未来。此外,耐多药(MDR)、完全耐药(TDR)和广泛耐药(XDR)结核分枝杆菌的出现增加了发现具有独特作用模式的新治疗方法的紧迫性。一些来源于放线菌的天然肽,如环马菌素 A、拉索霉素、鲁福霉素 I 和埃库霉素,对结核分枝杆菌具有强大而特异的杀菌活性,其特异性归因于这些肽靶向 ClpC1 ATP 酶,这是分枝杆菌中的一种必需酶,并抑制/激活参与蛋白质平衡的 ClpC1/P1/P2 复合物的蛋白水解活性。在这里,我们报告了 ClpC1 的 N 端结构域(ClpC1 NTD)与拉索霉素复合物的高分辨率晶体结构,显示了拉索霉素的特异性结合模式。此外,这项工作还比较了拉索霉素复合物结构与之前已知的 ClpC1 NTD 与其他天然肽(如环马菌素 A、鲁福霉素 I 和埃库霉素)复合物的结构。

相似文献

1
Crystal structure of the N-terminal domain of MtClpC1 in complex with the anti-mycobacterial natural peptide Lassomycin.MtClpC1N 端结构域与抗结核天然肽 Lassomycin 的复合物的晶体结构
Int J Biol Macromol. 2023 Dec 31;253(Pt 2):126771. doi: 10.1016/j.ijbiomac.2023.126771. Epub 2023 Sep 6.
2
Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.利福霉素靶向结核分枝杆菌和脓肿分枝杆菌的 ClpC1 蛋白酶解。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02204-18. Print 2019 Mar.
3
Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions.ClpC1 N 端结构域与抗结核天然产物埃卡霉素复合物的结构揭示了独特的结合相互作用。
Acta Crystallogr D Struct Biol. 2020 May 1;76(Pt 5):458-471. doi: 10.1107/S2059798320004027. Epub 2020 Apr 23.
4
Structure of the drug target ClpC1 unfoldase in action provides insights on antibiotic mechanism of action.药物靶标 ClpC1 解折叠酶的结构在作用中提供了对抗生素作用机制的深入了解。
J Biol Chem. 2022 Nov;298(11):102553. doi: 10.1016/j.jbc.2022.102553. Epub 2022 Oct 6.
5
The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from .抗生素环玛琳阻断 ClpC1 N 端结构域中精氨酸-磷酸诱导的毫秒级动力学。
J Biol Chem. 2018 Jun 1;293(22):8379-8393. doi: 10.1074/jbc.RA118.002251. Epub 2018 Apr 9.
6
High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.ClpC1-鲁佛霉素的高分辨率结构及配体结合研究为设计和优化抗结核先导化合物提供了框架。
ACS Infect Dis. 2019 Jun 14;5(6):829-840. doi: 10.1021/acsinfecdis.8b00276. Epub 2019 May 3.
7
Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.来自天然产物的靶向结核分枝杆菌ClpC1的抗结核先导分子。
J Ind Microbiol Biotechnol. 2016 Mar;43(2-3):205-12. doi: 10.1007/s10295-015-1709-3. Epub 2015 Nov 19.
8
The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.靶向ClpC1的环肽ecumicin在体内对结核分枝杆菌具有活性。
Antimicrob Agents Chemother. 2015 Feb;59(2):880-9. doi: 10.1128/AAC.04054-14. Epub 2014 Nov 24.
9
Identification of the inhibitory mechanism of ecumicin and rufomycin 4-7 on the proteolytic activity of Mycobacterium tuberculosis ClpC1/ClpP1/ClpP2 complex.鉴定依克米辛和罗呋木霉素 4-7 对结核分枝杆菌 ClpC1/ClpP1/ClpP2 复合物蛋白水解活性的抑制机制。
Tuberculosis (Edinb). 2023 Jan;138:102298. doi: 10.1016/j.tube.2022.102298. Epub 2022 Dec 24.
10
Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2.拉索霉素是一种核糖体合成的环肽,通过作用于ATP依赖性蛋白酶ClpC1P1P2来杀死结核分枝杆菌。
Chem Biol. 2014 Apr 24;21(4):509-518. doi: 10.1016/j.chembiol.2014.01.014. Epub 2014 Mar 27.

引用本文的文献

1
Enhancing rufomycin production by CRISPR/Cas9-based genome editing and promoter engineering in sp. MJM3502.通过基于CRISPR/Cas9的基因组编辑和启动子工程提高链霉菌MJM3502中鲁夫霉素的产量。
Synth Syst Biotechnol. 2025 Jan 17;10(2):421-432. doi: 10.1016/j.synbio.2025.01.002. eCollection 2025 Jun.
2
Identification of new ClpC1-NTD binders for Mycobacterium tuberculosis drug development.鉴定用于结核分枝杆菌药物开发的新型ClpC1-NTD结合剂。
Sci Rep. 2025 Feb 3;15(1):4146. doi: 10.1038/s41598-025-87535-1.